University of Minnesota has invested in UBC spinout AbCellera's series B round that also included Eli Lilly.
AbCellera, a Canada-based developer of an antibody drug discovery platform based on University of British Columbia research, completed a $105m series B round yesterday that featured University of Minnesota.
OrbiMed and DCVC Bio co-led the round, which also included pharmaceutical firm Eli Lilly, Viking Global Investors, Founders Fund, Presight Capital and private investor Peter Thiel.
Founded in 2012, AbCellera has created a technology platform that uses machine learning and data science to locate antibodies in natural immune systems…
